Pharma Q4 Results Preview: Bristol, Allergan, Gilead, GSK, Sanofi, Teva
Hemophilia and immuno-oncology will be in the spotlight as earnings season continues into February. Will Bristol be a buyer or an acquisition target? How will Sanofi fare with its new acquisitions? And how will Teva and GSK fare as they face generics for top brands?
You may also be interested in...
Pfizer Mum On Consumer Business Plans As Analysts Say Spin-off
Pfizer continues to review options for its consumer business, though analysts say a spin-off makes most sense. During its fourth-quarter earnings call, firm reported the division's US sales slumped 9% but 12% growth in international markets buoyed the worldwide results.
Namenda XR Generics Coming Soon? US Court Rulings Clear Path For Multiple Launches
Seven companies hold final ANDA approval for Alzheimer's drug, but Allergan still has chance to block them as it seeks rehearing of appeals court's patent decision. Meanwhile, Amneal might block other generics if it can get an appeals court to grant it the 180-day marketing exclusivity for memantine extended-release it says that FDA unfairly denied it.
AbbVie Expects 9% Tax Rate, Thanks To US Tax Reform Law
The tax reform windfall makes an already strong fourth quarter and full year 2017 financial report more impressive for AbbVie, which reported continuing growth for Humira and Imbruvica, and a big uptick in HCV.